Individuals who take eculizumab (Soliris®), a medication often prescribed for paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome, are also at a higher risk for the disease.
Having a low level of serum bactericidal antibody (SBA) has also been associated with a higher risk of meningococcal disease. Due to genetic and biological factors, a small minority of the population are unable to develop protective antibodies against meningococcal bacteria and have up to a 7,000 times greater risk of developing invasive meningococcal disease in their lifetime.
Learn about meningococcal disease complications.
